| Literature DB >> 35949217 |
Xiao-Ding Zhou1, Hong-Gang Wei2, Fu-Lu Ai3.
Abstract
BACKGROUND: With the change in people's lifestyles, the incidence of colorectal cancer (CRC) is increasing. It is essential to study the efficacy of various treatment methods for CRC patients to prevent and treat CRC. AIM: To investigate the efficacy of biofeedback therapy combined with Baduanjin in improving the quality of life and gastrointestinal hormone levels of patients with CRC.Entities:
Keywords: Baduanjin; Biofeedback therapy; Clinical efficacy; Colorectal cancer; Gastrointestinal hormone level; Quality of life
Year: 2022 PMID: 35949217 PMCID: PMC9244983 DOI: 10.4251/wjgo.v14.i6.1187
Source DB: PubMed Journal: World J Gastrointest Oncol
General data of four groups of patients (n = 112, mean ± SD)
|
|
|
|
|
|
|
|
| Number of cases (Male/female) | 15/14 | 16/12 | 15/13 | 15/12 | 0.19 | 0.98 |
| Age (yr) | 52.89 ± 6.43 | 53.93 ± 7.63 | 52.79 ± 5.85 | 54.70 ± 6.29 | 0.53 | 0.66 |
| BMI | 21.17 ± 1.35 | 21.49 ± 1.02 | 21.55 ± 1.14 | 20.95 ± 1.32 | 1.49 | 0.22 |
| Operation site/case | 0.93 | 0.99 | ||||
| Left colon | 8 | 8 | 6 | 8 | ||
| Right colon | 6 | 7 | 8 | 6 | ||
| Rectum | 15 | 13 | 14 | 13 |
BMI: Body mass index.
Clinical efficacy of four groups
|
|
|
|
|
|
|
|
| Group A | 29 | 1 | 6 | 8 | 14 | 51.72% |
| Group B | 28 | 3 | 8 | 8 | 9 | 67.86% |
| Group C | 28 | 3 | 11 | 6 | 8 | 71.43% |
| Group D | 27 | 7 | 14 | 4 | 2 | 92.59% |
P < 0.05, between group D, group A, group B and group C 12 wk after intervention.
P < 0.01, between group D, group A, group B and group C 12 wk after intervention.
Symptom scoring scale of constipation (mean ± SD, score)
|
|
|
|
| Group A | 16.52 ± 0.91 | 16.14 ± 0.99 |
| Group B | 16.36 ± 1.03 | 12.25 ± 1.93 |
| Group C | 16.39 ± 0.96 | 12.11 ± 1.93 |
| Group D | 16.22 ± 1.12 | 9.52 ± 1.72 |
P < 0.01, the intra-group comparison of each group at different time points.
P < 0.01, the comparison of group B, group C and group D with the group A at the same time point.
QLQ-CR38 scores of four groups before and after treatment (mean ± SD, min)
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
| |
| Functional dimension | ||||||||
| Body image | 43.17 ± 16.45 | 49.45 ± 12.25 | 41.32 ± 16.77 | 50.46 ± 13.24 | 43.43 ± 17.16 | 53.43 ± 15.05 | 42.48 ± 13.38 | 79.78 ± 13.75 |
| Future expectation | 42.48 ± 13.27 | 47.48 ± 11.83 | 42.14 ± 14.42 | 61.93 ± 15.58 | 43.64 ± 16.65 | 62.75 ± 15.16 | 41.52 ± 15.60 | 80.48 ± 10.68 |
| Sexual function | 23.45 ± 9.49 | 30.45 ± 12.65 | 24.32 ± 8.35 | 35.82 ± 12.42 | 22.64 ± 8.13 | 36.46 ± 11.55 | 23.48 ± 9.37 | 43.33 ± 13.38 |
| Sexual satisfaction | 38.52 ± 12.42 | 43.30 ± 13.72 | 39.07 ± 11.26 | 52.29 ± 11.92 | 40.07 ± 14.27 | 53.71 ± 12.60 | 39.33 ± 13.21 | 65.07 ± 14.07 |
| Symptom dimension | ||||||||
| Urination problem | 45.28 ± 14.14 | 42.38 ± 12.05 | 44.86 ± 13.64 | 35.29 ± 10.73 | 46.18 ± 12.16 | 35.29 ± 12.39 | 44.56 ± 13.60 | 23.44 ± 7.80 |
| Gastrointestinal symptoms | 37.34 ± 13.55 | 35.45 ± 11.06 | 38.46 ± 16.65 | 28.50 ± 12.71 | 37.21 ± 15.35 | 27.54 ± 10.85 | 38.44 ± 14.19 | 17.63 ± 9.37 |
| Adverse reactions of chemotherapy | 14.34 ± 4.53 | 29.28 ± 6.64 | 15.54 ± 7.09 | 26.18 ± 7.49 | 15.46 ± 5.90 | 25.96 ± 5.98 | 15.26 ± 5.16 | 18.41 ± 4.91 |
| Defecation problem | 23.52 ± 9.70 | 35.38 ± 8.67 | 24.18 ± 8.64 | 30.18 ± 7.83 | 23.43 ± 7.36 | 29.82 ± 9.29 | 24.56 ± 8.16 | 26.33 ± 6.52 |
| Issue related to stoma | 50.45 ± 11.30 | 44.52 ± 11.23 | 50.50 ± 10.90 | 36.29 ± 9.08 | 49.54 ± 12.23 | 38.18 ± 6.91 | 49.33 ± 11.68 | 24.74 ± 6.76 |
| Male sexual problems | 60.83 ± 14.90 | 51.07 ± 13.44 | 62.11 ± 11.25 | 45.71 ± 12.18 | 60.93 ± 14.03 | 43.64 ± 10.73 | 61.56 ± 13.27 | 42.63 ± 11.08 |
| Female sexual problems | 26.72 ± 8.69 | 23.38 ± 5.80 | 27.43 ± 7.71 | 21.68 ± 5.83 | 27.86 ± 6.90 | 20.36 ± 5.70 | 27.52 ± 8.10 | 18.30 ± 5.77 |
| Body mass | 54.48 ± 14.19 | 49.41 ± 11.97 | 55.32 ± 13.65 | 41.11 ± 9.87 | 55.18 ± 11.44 | 42.68 ± 11.67 | 55.11 ± 16.54 | 34.74 ± 9.65 |
P < 0.05, the intra-group comparison of each group at different time points.
P < 0.01, the intra-group comparison of each group at different time points.
P < 0.05, the comparison of group B, group C and group D with the group A at the same time point.
P < 0.01, the comparison of group B, group C and group D with the group A at the same time point.
Gastrointestinal hormone levels in peripheral blood of four groups (mean ± SD, pg·mL-1)
|
|
|
| ||
|
|
|
|
| |
| Group A | 146.07 ± 28.42 | 159.28 ± 25.69 | 120.17 ± 21.84 | 124.52 ± 23.38 |
| Group B | 151.75 ± 25.54 | 192.79 ± 22.75 | 131.18 ± 22.11 | 110.36 ± 22.49 |
| Group C | 147.57 ± 20.43 | 189.46 ± 25.06 | 125.36 ± 19.81 | 114.14 ± 21.10 |
| Group D | 144.52 ± 22.41 | 269.33 ± 24.74 | 119.52 ± 21.12 | 70.26 ± 20.53 |
P < 0.01, the intra-group comparison of each group at different time points.
P < 0.01, the comparison between group d, group a, group b and group c at the same time point.
MTL: Levels of motilin; SS: Levels of somatostatin.
Correlation between gastrointestinal hormone levels and scores of functional areas of quality of life in colorectal cancer patients (R)
|
|
|
|
|
| Body image | -0.376 | 0.617 | -0.532 |
| Future expectation | -0.530 | 0.569 | -0.446 |
| sexual function | -0.334 | 0.290 | -0.243 |
| Sexual satisfaction | -0.375 | 0.369 | -0.250 |
| Urination problem | 0.393 | -0.448 | 0.334 |
| Gastrointestinal symptoms | 0.436 | -0.390 | 0.238 |
| Adverse reactions of chemotherapy | 0.329 | -0.431 | 0.305 |
| Defecation problem | 0.265 | -0.002 | 0.166 |
| Issue related to stoma | 0.507 | -0.528 | 0.410 |
| Male sexual problems | 0.151 | -0.643 | 0.803 |
| Female sexual problems | 0.305 | -0.244 | 0.190 |
| Body mass | 0.314 | -0.284 | 0.195 |
P < 0.05, between gastrointestinal hormone levels and scores of functional areas of quality of life in colorectal cancer patients.
P < 0.01, between gastrointestinal hormone levels and scores of functional areas of quality of life in colorectal cancer patients.
MTL: Levels of motilin; SS: Levels of somatostatin.